Cerity Partners
PRLD icon

Cerity Partners’s Prelude Therapeutics PRLD Stock Holding History

Cerity Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
32,875
-78
-0.2% -$205 ﹤0.01% 3006
2025
Q4 		$95.6K Sell
32,953
-1,380
-4% -$2.33K ﹤0.01% 2754
2025
Q3 		$49.4K Sell
34,333
-2,060
-6% -$2.06K ﹤0.01% 2697
2025
Q2 		$29.5K Buy
36,393
+1,828
+5% +$1.58K ﹤0.01% 2590
2025
Q1 		$26.5K Buy
34,565
+1,688
+5% +$1.57K ﹤0.01% 2434
2024
Q4 		$68.1K Buy
32,877
+2
+0% +$3 ﹤0.01% 2369
2024
Q3 		$68.1K Buy
+32,875
New +$152K ﹤0.01% 2462
2024
Q2 		– Sell
-32,500
Closed -$154K – 2374
2024
Q1 		$154K Buy
+32,500
New +$126K ﹤0.01% 2155

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Cerity Partners's PRLD Position: Q1 2026 in Review

Cerity Partners reduced its Prelude Therapeutics (PRLD) stake by 0.24% in Q1 2026, selling an estimated $205 and leaving 32,875 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #3006.

Cerity Partners first reported a position in PRLD in Q1 2024 and has held it in 8 quarters since. The position peaked at $154K in Q1 2024. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Cerity Partners held 32,875 shares of Prelude Therapeutics worth $112K as of Q1 2026.
  • Cerity Partners sold 78 Prelude Therapeutics shares in Q1 2026, an estimated $205.
  • Prelude Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3006 holding.
  • Cerity Partners first reported a position in Prelude Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Cerity Partners's Prelude Therapeutics position peaked at $154K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.